The supply of GLP-1 drugs for weight loss and diabetes treatment is expected to tighten with a federal deadline to halt off-brand products.

The telehealth site will welcome its own small-dose, compounded version of semaglutide, which mimics the function of a GLP-1.

As of late 2024, only 14 state Medicaid programs cover GLP-1 drugs like Wegovy, Saxenda, or Zepbound for the treatment of obesity. These states are: California, Connecticut, Indiana, Maryland, ...

The FDA has approved medications like Zepbound and Wegovy for weight loss, which use the same active ingredient as the ...

As its obesity medication Wegovy loses a sizable portion of the market to Eli Lilly and Company (NYSE:LLY)’s competing ...

Online weight-loss company Noom has begun offering smaller doses of compounded versions of Novo Nordisk's Wegovy as the U.S.

Online weight loss company Noom has begun offering smaller doses of compounded versions of Novo Nordisk's Wegovy ...

Compounding pharmacies are supposed to stop producing the compounded versions of the popular weight loss medications now that ...

Novo Nordisk’s new top executive will need to help the company close the gap with Eli Lilly, fend off emerging rivals and ...

Novo has a strong balance sheet and ended 2024 with about DKK 26 billion in cash and marketable securities and DKK 103 billion of debt (following the acquisition of Catalent manufacturing sites in ...

Tirzepatide (Zepbound) led to more weight loss than semaglutide (Wegovy) in a clinical trial funded by Eli Lilly.

The success of Eli Lilly & Co. 's weight-loss and diabetes drugs has pushed the company's stock to new heights, helping the ...